These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 18070940

  • 1. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V, TNT Steering Committee and Investigators.
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [Abstract] [Full Text] [Related]

  • 2. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators.
    N Engl J Med; 2005 Apr 07; 352(14):1425-35. PubMed ID: 15755765
    [Abstract] [Full Text] [Related]

  • 3. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.
    Diabetes Care; 2006 Jun 07; 29(6):1220-6. PubMed ID: 16731999
    [Abstract] [Full Text] [Related]

  • 4. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1448-54. PubMed ID: 18402899
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets (TNT) Steering Committee and Investigators.
    Am J Cardiol; 2007 Sep 01; 100(5):747-52. PubMed ID: 17719314
    [Abstract] [Full Text] [Related]

  • 6. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 01; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ, Hunninghake DB, ALLIANCE Investigators.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1772-9. PubMed ID: 15519006
    [Abstract] [Full Text] [Related]

  • 9. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
    Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL.
    Am J Cardiol; 2011 Jan 15; 107(2):145-50. PubMed ID: 21129718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D, Bakker-Arkema RG, Wigand JP, Drehobl M, Schrott H, Early JL, Abdallah P, McBride S, Black DM.
    J Fam Pract; 1998 Nov 15; 47(5):349-56. PubMed ID: 9834769
    [Abstract] [Full Text] [Related]

  • 12. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators.
    J Hypertens; 2009 May 15; 27(5):947-54. PubMed ID: 19318984
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 May 15; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 14. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators.
    Clin J Am Soc Nephrol; 2007 Nov 15; 2(6):1131-9. PubMed ID: 17942759
    [Abstract] [Full Text] [Related]

  • 15. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H, Japanese Elderly Diabetes Intervention Trial Research Group.
    Geriatr Gerontol Int; 2012 Apr 15; 12 Suppl 1():88-102. PubMed ID: 22435944
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Apr 15; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.
    Diabetes Care; 2006 Jul 15; 29(7):1478-85. PubMed ID: 16801565
    [Abstract] [Full Text] [Related]

  • 19. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
    Athyros VG, Kakafika AI, Papageorgiou AA, Paraskevas KI, Tziomalos K, Anagnostis P, Pagourelias E, Koumaras C, Karagiannis A, Mikhailidis DP.
    Curr Med Res Opin; 2008 Jun 15; 24(6):1593-9. PubMed ID: 18430270
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.